BiTE antibodies offer another method for engaging the immune system with lymphoma by creating molecules with separate antigen binding sites targeting both tumor antigen (in the case of GCB lymphoma, CD19 or CD20) and a TCR-activating surface receptor, such as CD3. This evidence concerns the gene CD19 and lymphoma.